The Waldron LP Acquires New Position in Bristol-Myers Squibb Co (BMY)

The Waldron LP Acquires New Position in Bristol-Myers Squibb Co (BMY)

A number of other hedge funds have also recently bought and sold shares of BMY. American National Bank increased its stake in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 508 shares in the last quarter. Welch Investments LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at about $119,000. State of Alaska Department of Revenue increased its stake in shares of Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 60 shares in the last quarter. Prentiss Smith & Co. Inc. increased its stake in shares of Bristol-Myers Squibb by 61.8% in the first quarter. Prentiss Smith & Co. Inc. now owns 2,333 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 891 shares in the last quarter. Finally, Gradient Investments LLC increased its stake in shares of Bristol-Myers Squibb by 9.1% in the first quarter. Gradient Investments LLC now owns 2,401 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 200 shares in the last quarter. 69.67% of the stock is currently owned by institutional investors.

Waldron LP bought a new stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the first quarter, Holdings Channel reports. The firm bought 8,749 shares of the biopharmaceutical company’s stock, valued at approximately $475,000.

Bristol-Myers Squibb Co (BMY) opened at 54.97 on Monday. The stock has a 50 day moving average price of $54.46 and a 200-day moving average price of $55.23. The stock has a market capitalization of $90.56 billion, a P/E ratio of 19.09 and a beta of 1.00. Bristol-Myers Squibb Co has a 12-month low of $46.01 and a 12-month high of $77.12. Bristol-Myers Squibb also was the recipient of some unusual options trading on Friday. Stock traders purchased 18,916 put options on the company. This is an increase of approximately 139% compared to the average daily volume of 7,901 put options.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $0.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.12. The firm had revenue of $4.93 billion during the quarter, compared to analysts’ expectations of $4.75 billion. Bristol-Myers Squibb had a return on equity of 31.39% and a net margin of 22.94%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.74 earnings per share. Equities research analysts expect that Bristol-Myers Squibb Co will post $2.95 EPS for the current year.

Several analysts have recently issued reports on BMY shares. Deutsche Bank AG restated a “hold” rating and issued a $42.00 price objective on shares of Bristol-Myers Squibb in a research report on Thursday, February 16th. Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $57.15 price objective on the stock in a research report on Tuesday, March 14th. Piper Jaffray Companies restated a “neutral” rating and issued a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, March 8th. BMO Capital Markets restated a “market perform” rating and issued a $45.00 price objective on shares of Bristol-Myers Squibb in a research report on Sunday, April 23rd. Finally, Gabelli reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Thursday, February 9th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $62.57. In related news, Director Lamberto Andreotti sold 34,000 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, March 28th. The stock was sold at an average price of $56.17, for a total transaction of $1,909,780.00. Following the completion of the sale, the director now owns 986,112 shares of the company’s stock, valued at $55,389,911.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Louis S. Schmukler sold 5,000 shares of Bristol-Myers Squibb stock in a transaction on Friday, March 17th. The shares were sold at an average price of $56.49, for a total value of $282,450.00. Following the sale, the insider now directly owns 21,483 shares of the company’s stock, valued at approximately $1,213,574.67. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,096 shares of company stock valued at $5,421,270. Insiders own 0.24% of the company’s stock.

About Bristol-Myers Squibb Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “BMY”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Related posts

Leave a Comment